There are 23 resources available
Second line and third line treatments
Presenter: P. Montenegro, PE
Session: Session 3 - Treatment of advanced disease
Resources:
Slides
Participants clinical case discussion: HER 2 heterogeneity in a PDL1 positive metastatic gastric adenocarcinoma
Presenter: A. Licio Júnior, BR
Session: Session 3 - Treatment of advanced disease
Resources:
Slides
Participants clinical case discussion: Atypical evolution of HER2+/dMMR metastatic gastric cancer
Presenter: G. Catani, AR
Session: Session 3 - Treatment of advanced disease
Resources:
Slides
Sequencing HER2 directed therapy
Presenter: A. Cervantes, ES
Session: Session 4 - Biomarker targeted therapy and immunotherapy
Resources:
Slides
Immunotherapy new challenges
Presenter: M. Garrido, CL
Session: Session 4 - Biomarker targeted therapy and immunotherapy
Resources:
Slides
Emerging therapies; claudin 18.2, FGFR2, etc.
Presenter: T. Fleitas, ES
Session: Session 4 - Biomarker targeted therapy and immunotherapy
Resources:
Slides
DEBATE: Patients with oligometastatic gastroesophageal cancer should be surgical candidates - YES
Presenter: A. Nieponice, AR
Session: Session 5 - Oligometastatic gastroesophageal cancer
Resources:
Slides
DEBATE: Patients with oligometastatic gastroesophageal cancer should be surgical candidates - NO
Presenter: G. Mendez, AR
Session: Session 5 - Oligometastatic gastroesophageal cancer
Resources:
Slides
Participants clinical case discussion: Oligometastatic dMMR/MSI gastric cancer
Presenter: A. M. Luna Meza, CO
Session: Session 5 - Oligometastatic gastroesophageal cancer
Resources:
Slides
Participants clinical case discussion: Gastroesophageal adenocarcinoma with hepatoid differentiation: Oligometastatic management
Presenter: M. Bortz, AR
Session: Session 5 - Oligometastatic gastroesophageal cancer
Resources:
Slides